SOUTH SAN FRANCISCO, Calif., Feb. 23 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that it will release results for the fourth quarter and year end 2005 after close of the stock market on Wednesday, March 8, 2006.
Company management will also host a conference call at 2:00 p.m. PT on March 8, 2006 to discuss fourth quarter 2005 and year-end 2005 results. The dial-in number for domestic callers will be 800-309-2906, and for international callers will be 706-634-0903. The passcode for both domestic and international callers is 5538898.
To listen to the live webcast of the conference call please go to www.cotherix.com and click on the "Investor Relations" link. There will be a replay available for approximately two weeks following the call. The conference call, replay and webcast are open to all interested parties.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix's Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com
CoTherix, Inc.CONTACT: Anne Bowdidge, Senior Director of Investor Relations of CoTherix,Inc., +1-650-808-6551
